Site Map
Links
Investors
Product Pipeline
TargeGen Pipeline
Molecule
Targets
Indications
Status
TG101348(oral)
Jak2, Flt3, Ret
Myelofibrosis
Phase I study completed.
©2004 TargeGen Inc.
